Figure 1: RAP1 does not bind DNA, does not affect TRF2 binding on linear DNA, and can form a ternary complex with TRF2 and tel H-J. A: ITC experiments performed at 10°C with RAP1 and double-stranded DNA oligonucleotides in 50 mM Tris pH 7.5, 150 mM NaCl, 10 mM β-ME. B: EMSA performed on 5 nM of a labelled 54 bp linear DNA that contains 4 telomeric repeats (dsT4) using 40 nM of TRF2 dimers and increasing amounts of RAP1. The addition of RAP1 causes a slight change in the aspect of TRF2-containing complexes but no visible changes in affinity. C: EMSA performed on 5 nM of a labelled 106 bp linear DNA containing 16 telomeric repeats (dsT16) using 10 nM of TRF2 dimers and increasing amounts of RAP1. The addition of RAP1 causes both a slight change in the aspect of the TRF2-containing complex and a mild increase in affinity (~10% increase in the amount of complex). D: Drawing of telomeric Holliday Junction (tHJ), a migratable Holliday Junction with 27 bp including 1 telomeric repeat per arm. E: EMSA performed on labelled tHJ (5 nM) using 20 nM of TRF2 dimers and increasing amounts of RAP1. The addition of RAP1 causes a change in the aspect of TRF2-containing complexes but no overt modification of affinity. 
Supplementary Figure 2: RAP1 totally inhibits TRF2-dependent protection against CCE1 and RusA cleavage of tHJ, and largely inhibits TRF2-dependent protection against Endonuclease I cleavage of tHJ. A-B: 5 nM of tHJ labelled on either strand 2 (A) or 4 (B) was incubated with 200 nM of TRF2 with and without increasing amount of RAP1 prior to cleavage with either CCE1 A or RusA . Concentrations of RAP1 used were 100, 200, 400, 1000, 1500 nM. In lanes 3, 11 and 18, the junction is incubated with 1500 nM of RAP1. C-F: 5 nM of tHJ labelled on either of the 4 strands was incubated with 200 nM of TRF2 with and without increasing amount of RAP1 prior to cleavage with Endonuclease I. Concentrations of RAP1 used were 100, 200, 400, 1000, 1500 nM. In lanes 3 and 10, the junction is incubated with 1500 nM of RAP1. Distance distribution probability A: summary of footprinting results in TRF2 (K58 to K267). Lysine residues protected (blue) or not affected (grey) in TRF2/RAP1 and TRF2/ARAGA complex, or protected only in TRF2/RAP1 complex (green). Region protected in TRF2/RAP1 and TRF2/ ARAGA complex, but precise lysine undetermined (light blue). Lysine residues not detected, or with signal too weak to be interpreted (white). B-F: MS peaks of interest, with corresponding fragment indicated above each peak. Lysine residues are colorcoded according to A, acetylated lysines are underlined, and number of acetyl groups in each fragment is indicated. Red and orange curves: TRF2 alone; dark blue and blue curves: TRF2 in complex with RAP1 (with ARAGA in D, right panel). Supplementary Figure 8 (continued) G: summary of footprinting results in TRF2 (K289 to K495). Lysine residues protected (blue), more accessible (red) or not affected (grey) in TRF2/RAP1 and TRF2/ARAGA complex. Region protected in TRF2/RAP1 and TRF2/ARAGA complex, but precise lysine undetermined (light blue). Lysine residues not detected, or with signal too weak to be interpreted (white). H-K: MS peaks of interest, with corresponding fragment indicated above each peak. Lysine residues are color-coded according to G, acetylated lysines are underlined, and number of acetyl groups in each fragment is indicated. Red and orange curves: TRF2 alone; dark blue and blue curves: TRF2 in complex with RAP1. 
